Stableford Capital II LLC Buys New Stake in Boston Scientific Co. (NYSE:BSX)

Stableford Capital II LLC purchased a new position in Boston Scientific Co. (NYSE:BSX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 9,279 shares of the medical equipment provider’s stock, valued at approximately $829,000.

A number of other hedge funds also recently bought and sold shares of BSX. Western Financial Corp CA purchased a new stake in shares of Boston Scientific during the 4th quarter valued at about $741,000. China Universal Asset Management Co. Ltd. bought a new stake in Boston Scientific during the fourth quarter worth approximately $1,174,000. Waldron Private Wealth LLC increased its stake in Boston Scientific by 100.8% during the fourth quarter. Waldron Private Wealth LLC now owns 10,238 shares of the medical equipment provider’s stock worth $914,000 after acquiring an additional 5,140 shares during the last quarter. Caprock Group LLC raised its position in Boston Scientific by 11.4% during the fourth quarter. Caprock Group LLC now owns 51,835 shares of the medical equipment provider’s stock valued at $4,630,000 after purchasing an additional 5,323 shares during the period. Finally, Oak Harvest Investment Services lifted its stake in shares of Boston Scientific by 262.5% in the 4th quarter. Oak Harvest Investment Services now owns 40,776 shares of the medical equipment provider’s stock valued at $3,642,000 after purchasing an additional 29,526 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research report on Friday, January 10th. Bank of America increased their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Sanford C. Bernstein raised their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. TD Cowen upped their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, December 12th. Finally, Royal Bank of Canada raised their price objective on shares of Boston Scientific from $95.00 to $98.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Two investment analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $98.35.

Boston Scientific Price Performance

Shares of BSX opened at $102.40 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The company has a 50 day moving average price of $93.47 and a 200-day moving average price of $86.21. Boston Scientific Co. has a fifty-two week low of $62.63 and a fifty-two week high of $104.25. The stock has a market capitalization of $150.92 billion, a PE ratio of 84.63, a PEG ratio of 2.69 and a beta of 0.80.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the transaction, the executive vice president now owns 29,308 shares in the company, valued at $2,660,580.24. The trade was a 19.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the sale, the director now directly owns 39,398 shares of the company’s stock, valued at $3,610,038.74. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,989 shares of company stock valued at $2,702,261 over the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.